屈洛昔芬研究进展  

PROGRESS IN DROLOXIFENE RESEARCH

作　　者：张弘纲[1] 孙燕[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院

出　　处：《中国新药杂志》1998年第4期269-273,共5页Chinese Journal of New Drugs

摘　　要：目的：介绍新一代的雌激素激动／拮抗剂屈洛昔芬。方法：通过复习近１５年来的文献对屈洛昔芬的药理、药代动力学、毒理和临床研究进行综述。结果：屈洛昔芬对雌激素受体具有高亲和力，具有抗雌激素和雌激素样作用。对乳腺癌及绝经后妇女的骨质疏松具有治疗作用。结论：屈洛昔芬是一个内分泌治疗新药。OBJECTIVE:To introduce a new estrogen agonist/antagonist ,droloxifene.METHODS:The progresses in pharmacology,pharmacokinetics,toxicology and clinical trials of droloxifene in the last 15 years were reviewed.RESULTS:Droloxifene is an antiestrogenic and estrogenic agent having high affinity binding to estrogen receptor and it is effective in treatment of breast cancer and postmenopausal osteoporosis.CONCLUSION:Droloxifene,a new endocrinotherapeutic agent,is worthy to be studied in further for treatment of breast cancer and postmenopausal osteoporosis.

关 键 词：屈洛昔芬 药理 内分泌治疗 乳腺癌 骨质疏松 

分 类 号：R977[医药卫生—药品]